EP Patent

EP0577303B1 — Stereoselective glycosylation process

Assigned to Eli Lilly and Co · Expires 1997-10-01 · 29y expired

What this patent protects

A stereoselective glycosylation process for preparing beta anomer fluoronucleosides via the SN2 displacement of an anomeric sulfonyloxy group of an alpha anomer enriched fluorocarbohydrate with a nucleobase.

USPTO Abstract

A stereoselective glycosylation process for preparing beta anomer fluoronucleosides via the SN2 displacement of an anomeric sulfonyloxy group of an alpha anomer enriched fluorocarbohydrate with a nucleobase.

Drugs covered by this patent

Patent Metadata

Patent number
EP0577303B1
Jurisdiction
EP
Classification
—
Expires
1997-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.